EGFR and non-small cell lung carcinoma: The ADAURA trial, which investigated the use of osimertinib to treat EGFR-mutant NSCLC, demonstrated that extending therapy for up to three years significantly reduced the risk of relapse, suggesting that prolonged treatment may confer similar benefits in the immunotherapy setting [54].